Getting your Trinity Audio player ready...
Abbott Laboratories has withdrawn its application seeking U.S. Food and Drug Administration approval of its schizophrenia drug Serlect. The company decided to pull the application after talking with FDA officials, said company spokeswoman Melissa Brotz. She declined to give any specifics about the company’s decision or when the company might reapply. As far back as July 1996, the agency had expressed concerns about the safety of the drug.
